Psychotropic medication use in anorexia nervosa between 1997 and 2009

International Journal of Eating Disorders

Volumn 45, Issue 8, 2012, Pages 970-976

  Fazeli, Pouneh K ^a   Calder, Genevieve L ^a,b   Miller, Karen K ^a   Misra, Madhusmita ^a   Lawson, Elizabeth A ^a   Meenaghan, Erinne ^a   Lee, Hang ^a   Herzog, David ^a   Klibanski, Anne ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Anorexia Nervosa; Atypical Antipsychotic; SSRI

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; DIAZEPAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; LORAZEPAM; MIRTAZAPINE; MOCLOBEMIDE; NEFAZODONE; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PERPHENAZINE; PHENELZINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; UNINDEXED DRUG; VENLAFAXINE; ZIPRASIDONE;

ADULT; ANOREXIA NERVOSA; DRUG USE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; REVIEW;

ADOLESCENT; ADULT; ANOREXIA NERVOSA; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; COMORBIDITY; DRUG PRESCRIPTIONS; DRUG UTILIZATION; FEMALE; HUMANS; MASSACHUSETTS; MIDDLE AGED; PSYCHOTROPIC DRUGS; TREATMENT FAILURE; YOUNG ADULT;

EID: 84869493278     PISSN: 02763478     EISSN: 1098108X     Source Type: Journal    
DOI: 10.1002/eat.22037     Document Type: Review

References (47)

1. Lucas AR, Crowson CS, O'Fallon WM, Melton LJ, III,. The ups and downs of anorexia nervosa. Int J Eat Disord 1999; 26: 397-405.
2. Pope HG, Hudson JI, Yurgelun-Todd D, Hudson MS,. Prevalence of anorexia nervosa and bulimia in three student populations. Int J Eating Disord 1984; 3: 45-51.
3. Fichter MM, Quadflieg N, Hedlund S,. Twelve-year course and outcome predictors of anorexia nervosa. Int J Eat Disord 2006; 39: 87-100.
4. Lowe B, Zipfel S, Buchholz C, Dupont Y, Reas DL, Herzog W,. Long-term outcome of anorexia nervosa in a prospective 21-year follow-up study. Psychol Med 2001; 31: 881-890.
5. Sullivan PF,. Mortality in anorexia nervosa. Am J Psychiatry 1995; 152: 1073-1074.
6. Harris EC, Barraclough B,. Excess mortality of mental disorder. Br J Psychiatry 1998; 173: 11-53.
7. Keel PK, Dorer DJ, Eddy KT, Franko D, Charatan DL, Herzog DB,. Predictors of mortality in eating disorders. Arch Gen Psychiatry 2003; 60: 179-183.
8. Rosling AM, Sparen P, Norring C, von Knorring AL,. Mortality of eating disorders: A follow-up study of treatment in a specialist unit 1974-2000. Int J Eat Disord 2011; 44: 304-310.
9. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Eating Disorders TE. New York: American Psychiatric Association, 2006.
10. Claudino AM, Hay P, Lima MS, Bacaltchuk J, Schmidt U, Treasure J,. Antidepressants for anorexia nervosa. Cochrane Database Syst Rev 2006; 1: CD004365.
11. Mischoulon D, Eddy KT, Keshaviah A, Dinescu D, Ross SL, Kass AE, et al. Depression and eating disorders: treatment and course. J Affect Disord 2011; 130: 470-477.
12. Needleman HL, Waber D,. Letter: Amitriptyline therapy in patients with anorexia nervosa. Lancet 1976; 2: 580.
13. Mills IH,. Letter: Amitriptyline therapy in anorexia nervosa. Lancet 1976; 2: 687.
14. Hudson JI, Pope HG Jr, Jonas JM, Yurgelun-Todd D,. Treatment of anorexia nervosa with antidepressants. J Clin Psychopharmacol 1985; 5: 17-23.
15. Biederman J, Herzog DB, Rivinus TM, Harper GP, Ferber RA, Rosenbaum JF, et al. Amitriptyline in the treatment of anorexia nervosa: A double-blind, placebo-controlled study. J Clin Psychopharmacol 1985; 5: 10-16.
16. Attia E, Haiman C, Walsh BT, Flater SR,. Does fluoxetine augment the inpatient treatment of anorexia nervosa? Am J Psychiatry 1998; 155: 548-551.
17. Walsh BT, Kaplan AS, Attia E, Olmsted M, Parides M, Carter JC, et al. Fluoxetine after weight restoration in anorexia nervosa: A randomized controlled trial. JAMA 2006; 295: 2605-2612.
18. Haney EM, Chan BK, Diem SJ, Ensrud KE, Cauley JA, Barrett-Connor E, et al. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med 2007; 167: 1246-1251.
19. Diem SJ, Blackwell TL, Stone KL, Yaffe K, Haney EM, Bliziotes MM, et al. Use of antidepressants and rates of hip bone loss in older women: The study of osteoporotic fractures. Arch Intern Med 2007; 167: 1240-1245.
20. Richards JB, Papaioannou A, Adachi JD, Joseph L, Whitson HE, Prior JC, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 2007; 167: 188-194.
21. Ziere G, Dieleman JP, van der Cammen TJ, Hofman A, Pols HA, Stricker BH,. Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. J Clin Psychopharmacol 2008; 28: 411-417.
22. Verdel BM, Souverein PC, Egberts TC, van Staa TP, Leufkens HG, de Vries F,. Use of antidepressant drugs and risk of osteoporotic and non-osteoporotic fractures. Bone 2010; 47: 604-609.
23. O'Keane V, Meaney AM,. Antipsychotic drugs: A new risk factor for osteoporosis in young women with schizophrenia? J Clin Psychopharmacol 2005; 25: 26-31.
24. Bolton JM, Targownik LE, Leung S, Sareen J, Leslie WD,. Risk of low bone mineral density associated with psychotropic medications and mental disorders in postmenopausal women. J Clin Psychopharmacol 2011; 31: 56-60.
25. Brambilla F, Garcia CS, Fassino S, Daga GA, Favaro A, Santonastaso P, et al. Olanzapine therapy in anorexia nervosa: Psychobiological effects. Int Clin Psychopharmacol 2007; 22: 197-204.
26. Bissada H, Tasca GA, Barber AM, Bradwejn J,. Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: A randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2008; 165: 1281-1288.
27. Attia E, Kaplan AS, Walsh BT, Gershkovich M, Yilmaz Z, Musante D, et al. Olanzapine versus placebo for out-patients with anorexia nervosa. Psychol Med 2011; 41: 2177-2182.
28. Association AP,. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), 4th ed. Washington, DC: American Psychiatric Publishing; 1994.
29. Company MLI,. Height and weight tables. J Nutr Elderly 1983; 3: 23-26.
30. Ferguson JM,. Treatment of an anorexia nervosa patient with fluoxetine. Am J Psychiatry 1987; 144: 1239.
31. Gwirtsman HE, Guze BH, Yager J, Gainsley B,. Fluoxetine treatment of anorexia nervosa: An open clinical trial. J Clin Psychiatry 1990; 51: 378-382.
32. Kaye WH, Weltzin TE, Hsu LK, Bulik CM,. An open trial of fluoxetine in patients with anorexia nervosa. J Clin Psychiatry 1991; 52: 464-471.
33. Calandra C, Gulino V, Inserra L, Giuffrida A,. The use of citalopram in an integrated approach to the treatment of eating disorders: an open study. Eat Weight Disord 1999; 4: 207-210.
34. Frank GK, Kaye WH, Marcus MD,. Sertraline in underweight binge eating/purging-type eating disorders: Five case reports. Int J Eat Disord 2001; 29: 495-498.
35. Santonastaso P, Friederici S, Favaro A,. Sertraline in the treatment of restricting anorexia nervosa: An open controlled trial. J Child Adolesc Psychopharmacol 2001; 11: 143-150.
36. Fassino S, Leombruni P, Daga G, Brustolin A, Migliaretti G, Cavallo F, et al. Efficacy of citalopram in anorexia nervosa: A pilot study. Eur Neuropsychopharmacol 2002; 12: 453-459.
37. Ruggiero GM, Mauri MC, Omboni AC, Volonteri LS, Dipasquale S, Malvini L, et al. Nutritional management of anorexic patients with and without fluoxetine: 1-year follow-up. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 425-430.
38. Warden SJ, Robling AG, Sanders MS, Bliziotes MM, Turner CH,. Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth. Endocrinology 2005; 146: 685-693.
39. Stevens JR, Kymissis PI, Baker AJ,. Elevated prolactin levels in male youths treated with risperidone and quetiapine. J Child Adolesc Psychopharmacol 2005; 15: 893-900.
40. Lusskin SI, Cancro R, Chuang L, Jacobson J,. Prolactin elevation with ziprasidone. Am J Psychiatry 2004; 161: 1925.
41. Miller KK, Grinspoon SK, Ciampa J, Hier J, Herzog D, Klibanski A,. Medical findings in outpatients with anorexia nervosa. Arch Intern Med 2005; 165: 561-566.
42. Rigotti NA, Neer RM, Skates SJ, Herzog DB, Nussbaum SR,. The clinical course of osteoporosis in anorexia nervosa. A longitudinal study of cortical bone mass. JAMA 1991; 265: 1133-1138.
43. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-1696.
44. Zhang ZJ, Yao ZJ, Liu W, Fang Q, Reynolds GP,. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry 2004; 184: 58-62.
45. Gilles M, Hentschel F, Paslakis G, Glahn V, Lederbogen F, Deuschle M,. Visceral and subcutaneous fat in patients treated with olanzapine: A case series. Clin Neuropharmacol 2010; 33: 248-249.
46. Bredella MA, Torriani M, Ghomi RH, Thomas BJ, Brick DJ, Gerweck AV, et al. Determinants of bone mineral density in obese premenopausal women. Bone 2011; 48: 748-754.
47. Katzmarzyk PT, Barreira TV, Harrington DM, Staiano AE, Heymsfield SB, Gimble JM,. Relationship between abdominal fat and bone mineral density in white and African American adults. Bone 2012; 50: 576-579.